1459P Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)

Autor:	B. Escudier, R.J. Motzer, M. Dyer, J.R. May, F. Ejzykowicz, M. Kurt, C-W. Lee, P. Wang, E. Testa, D.J. Sharpe, S. George, N. Tannir
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S1212
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::014237d1603fde3034b50f1df70803c4 https://doi.org/10.1016/j.annonc.2022.07.1562 Zobrazit plný text záznamu